Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for STRO-004 in Cancer. The expected timing is based on the latest available company guidance and may change.
05/14/26:- Ph1 dose escalation progressing; initial safety, PK, and activity data remain expected Mid-2026. 08/12/26:- STRIVE-01 reported early responses and favorable tolerability. The next Ph1 study update and expansion cohorts are expected in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.